Legal & General expects record year for profits

Sean Farrell WebFG News | 07 Dec, 2017 07:38 - Updated: 08:41 | | |

legal and & general
  • 265.90
  • 0.45%1.20
  • Max: 266.40
  • Min: 263.90
  • Volume: 10,345,308
  • MM 200 : n/a
17:17 12/12/17
  • 7,500.41
  • 0.63%46.93
  • Max: 7,501.52
  • Min: 7,448.31
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 1,542.94
  • 0.79%12.11
  • Max: 1,542.94
  • Min: 1,529.33
  • Volume: 0
  • MM 200 : n/a
17:30 12/12/17
  • 8,611.33
  • -0.19%-16.06
  • Max: 8,648.95
  • Min: 8,572.07
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 4,167.58
  • 0.53%21.93
  • Max: 4,167.95
  • Min: 4,143.15
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 4,114.09
  • 0.53%21.50
  • Max: 4,114.10
  • Min: 4,090.46
  • Volume: 0
  • MM 200 : n/a
17:30 12/12/17
  • 0.00
  • 0.00%0.00
  • Max: n/a
  • Min: n/a
  • Volume: n/a
  • MM 200 : n/a
17:17 25/09/06

Legal & General said it expected a record year for profits and earnings as it reported accelerating growth across its businesses.

In a trading update, the insurer said it had “great momentum” in all its operations with particularly strong growth in recent weeks.

L&G’s retirement business has made £6.2bn in sales so far this year and investment management had total net inflows of £38.1bn at the end of October. Life insurance and protection gross written premiums rose 6% to £2.1bn at the end of October and general insurance gross written premiums were up 13% to £305m.

Nigel Wilson, Legal & General’s chief executive, said "L&G is on track for a record year for earnings and profits. Our core business divisions are generating formidable momentum. Our market leading positions and strong balance sheet, coupled with our management capability is allowing us to benefit from global growth opportunities."

L&G agreed on 6 December to sell its mature savings business to Swiss Re for £650m. Wilson said the sale left L&G able to focus on products and countries with the best growth potential.

More news

17:53 London close: Forties failure lifts FTSE as inflation spikes

London stocks extended their gains on Tuesday as supply disruptions boosted the energy sector and investors mulled higher than expected UK inflation figures.

17:33 US open: Boeing, 3M push Dow Industrials to fresh record-high

Wall Street's main indices are again heading higher on Tuesday as the Federal Reserve kicks off its two-day rate-setting meeting and several positive updates from corporate heavyweights such as Boeing and 3M.

17:34 EasyJet acquisition of Air Berlin assets approved by European Commission

UK budget airline easyJet cleared a major regulatory hurdle on Tuesday as its proposed acquisition of airport slots and aircraft from Air Berlin was approved by the European Commission.

17:49 Facebook to overhaul its tax structure worldwide

Facebook will move its global tax and revenue base from Ireland and begin booking advertising locally in every country where it operates.

16:51 GSK given green light for Churg-Strauss syndrome treatment

GlaxoSmithKline has been given approval by the US drug regulator for a first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.

16:44 Trump accuses Democrats of plot after sexual harassment claims

US President Donald Trump has claimed Democrats are behind a series of sexual harassment claims made against him this week.

16:41 Trump vows to send American astronauts to the moon

Donald Trump, the President of the United states signed the Space Policy Directive 1 to send astronauts to the moon again and to Mars for the first time in history.

16:33 Goldman Sachs keeps Barclays and Lloyds at 'sell'

Goldman Sachs reiterated its 'sell' recommendation on shares of Lloyds and Barclays, placing both stocks on its list of 'UK Sell Ideas' for 2018.

16:27 EU Brexit negotiator says David Davis comments 'undermine trust'

Brexit secretary David Davis’ claim that the deal agreed by the UK and European Union last week is not binding has been branded “unacceptable” by bloc negotiator Guy Verhofstadt, who added that it “undermines trust” between the two teams.

16:23 GlaxoSmithKline upbeat on 'promising' data from Dreamm-1 blood cancer study

GlaxoSmithKline has presented promising new data from the dose expansion phase of the Dreamm-1 study of GSK2857916, an anti-B-cell maturation antigen (BCMA) antibody-drug conjugate to treat blood cancer.